Outcomes of new pregnancy attempts in women from the thrombophilia group and no-thrombophilia group with prior fetal death
| . | Thrombophilia, 186 . | . | No-thrombophilia, 313 . | . | . | . |
|---|---|---|---|---|---|---|
| Group, N . | n/N . | Incidence . | n/N . | Incidence . | RR (95% CI)* . | P . |
| New pregnancies | 185/186 | 0.995 | 311/313 | 0.994 | ||
| Prophylactic LMWH treatment during pregnancy | 185/185 | 1 | 0/311 | 0 | ||
| Spontaneous abortions before 10 WG | 36/185 | 0.195 | 83/311 | 0.267 | 0.750 (0.533-1.056) | .0998 |
| Ongoing pregnancies at 10 WG | 149/185 | 0.805 | 228/311 | 0.740 | 1,090 (0.989-1.202) | .0835 |
| Fetal deaths (% of new pregnancies) | 19/185 | 0.103 | 72/311 | 0.232 | 0.444 (0.277-0.712) | .0007 |
| Fetal deaths (% of ongoing pregnancies at 10 WG) | 19/149 | 0.128 | 72/228 | 0.313 | 0.407 (0.257-0.646) | .0001 |
| Ongoing pregnancy at 20 WG (% of new pregnancies) | 139/185 | 0.751 | 180/311 | 0.579 | 1.299 (1.145-1.475) | .0001 |
| Live births (% of new pregnancies | 130/185 | 0.703 | 156/311 | 0.502 | 1.385 (1.198-1.600) | <.0001 |
| Live births (% of ongoing pregnancies at 10 WG) | 130/149 | 0.872 | 156/228 | 0.684 | 1.270 (1.142-1.413) | <.0001 |
| Preterm live births <37 WG (% of live births) | 16/130 | 0.123 | 39/156 | 0.250 | 0.499 (0.292-0.850) | .0106 |
| Preterm live births <34 WG (% of live births) | 7/130 | 0.054 | 19/156 | 0.122 | 0.448 (0.194-1.032) | .0593 |
| PE (% of ongoing pregnancies at 20 WG) | 12/139 | 0.086 | 21/180 | 0.117 | 0.740 (0.377-1.452) | .381 |
| Severe PE | 3/139 | 0.022 | 15/180 | 0.083 | 0.246 (0.073-0.833) | .0242 |
| PE <34 WG | 1/139 | 0.007 | 11/180 | 0.061 | 0.118 (0.015-0.901) | .0394 |
| Eclampsia | 1/139 | 0.007 | 5/180 | 0.028 | 0.259 (0.031-2.192) | .215 |
| HELLP syndrome | 1/139 | 0.007 | 4/180 | 0.022 | 0.324 (0.037-2.864) | .311 |
| SGA | 19/139 | 0.137 | 37/180 | 0.206 | 0.665 (0.401-1.104) | .115 |
| (% of ongoing pregnancies at 20 WG) | ||||||
| Severe SGA <p5 | 9/139 | 0.065 | 19/180 | 0.106 | 0.613 (0.286-1.314) | .209 |
| Very severe SGA <p3 | 4/139 | 0.029 | 12/180 | 0.067 | 0.432 (0.142-1.309) | .138 |
| PE+SGA | 5/139 | 0.036 | 13/180 | 0.072 | 0.498 (0.182-1.364) | .175 |
| PA (% of ongoing pregnancies at 20 WG) | 2/139 | 0.014 | 6/180 | 0.033 | 0.432 (0.089-2.106) | .299 |
| Placenta-mediated complications: PE and/or SGA and/or PA (% of ongoing pregnancies at 20 WG) | 26/139 | 0.187 | 50/180 | 0.278 | 0.673 (0.443-1.024) | .064 |
| NM (% of live births) | 2/130 | 0.015 | 4/156 | 0.026 | 0.608 (0.113-3.265) | .562 |
| Early NM, day 1-d 7 | 1/130 | 0.008 | 3/156 | 0.019 | 0.405 (0.043-3.849) | .432 |
| Late NM, day 8-d 27 | 1/130 | 0.008 | 1/156 | 0.006 | 1.215 (0.077-19.24) | .889 |
| . | Thrombophilia, 186 . | . | No-thrombophilia, 313 . | . | . | . |
|---|---|---|---|---|---|---|
| Group, N . | n/N . | Incidence . | n/N . | Incidence . | RR (95% CI)* . | P . |
| New pregnancies | 185/186 | 0.995 | 311/313 | 0.994 | ||
| Prophylactic LMWH treatment during pregnancy | 185/185 | 1 | 0/311 | 0 | ||
| Spontaneous abortions before 10 WG | 36/185 | 0.195 | 83/311 | 0.267 | 0.750 (0.533-1.056) | .0998 |
| Ongoing pregnancies at 10 WG | 149/185 | 0.805 | 228/311 | 0.740 | 1,090 (0.989-1.202) | .0835 |
| Fetal deaths (% of new pregnancies) | 19/185 | 0.103 | 72/311 | 0.232 | 0.444 (0.277-0.712) | .0007 |
| Fetal deaths (% of ongoing pregnancies at 10 WG) | 19/149 | 0.128 | 72/228 | 0.313 | 0.407 (0.257-0.646) | .0001 |
| Ongoing pregnancy at 20 WG (% of new pregnancies) | 139/185 | 0.751 | 180/311 | 0.579 | 1.299 (1.145-1.475) | .0001 |
| Live births (% of new pregnancies | 130/185 | 0.703 | 156/311 | 0.502 | 1.385 (1.198-1.600) | <.0001 |
| Live births (% of ongoing pregnancies at 10 WG) | 130/149 | 0.872 | 156/228 | 0.684 | 1.270 (1.142-1.413) | <.0001 |
| Preterm live births <37 WG (% of live births) | 16/130 | 0.123 | 39/156 | 0.250 | 0.499 (0.292-0.850) | .0106 |
| Preterm live births <34 WG (% of live births) | 7/130 | 0.054 | 19/156 | 0.122 | 0.448 (0.194-1.032) | .0593 |
| PE (% of ongoing pregnancies at 20 WG) | 12/139 | 0.086 | 21/180 | 0.117 | 0.740 (0.377-1.452) | .381 |
| Severe PE | 3/139 | 0.022 | 15/180 | 0.083 | 0.246 (0.073-0.833) | .0242 |
| PE <34 WG | 1/139 | 0.007 | 11/180 | 0.061 | 0.118 (0.015-0.901) | .0394 |
| Eclampsia | 1/139 | 0.007 | 5/180 | 0.028 | 0.259 (0.031-2.192) | .215 |
| HELLP syndrome | 1/139 | 0.007 | 4/180 | 0.022 | 0.324 (0.037-2.864) | .311 |
| SGA | 19/139 | 0.137 | 37/180 | 0.206 | 0.665 (0.401-1.104) | .115 |
| (% of ongoing pregnancies at 20 WG) | ||||||
| Severe SGA <p5 | 9/139 | 0.065 | 19/180 | 0.106 | 0.613 (0.286-1.314) | .209 |
| Very severe SGA <p3 | 4/139 | 0.029 | 12/180 | 0.067 | 0.432 (0.142-1.309) | .138 |
| PE+SGA | 5/139 | 0.036 | 13/180 | 0.072 | 0.498 (0.182-1.364) | .175 |
| PA (% of ongoing pregnancies at 20 WG) | 2/139 | 0.014 | 6/180 | 0.033 | 0.432 (0.089-2.106) | .299 |
| Placenta-mediated complications: PE and/or SGA and/or PA (% of ongoing pregnancies at 20 WG) | 26/139 | 0.187 | 50/180 | 0.278 | 0.673 (0.443-1.024) | .064 |
| NM (% of live births) | 2/130 | 0.015 | 4/156 | 0.026 | 0.608 (0.113-3.265) | .562 |
| Early NM, day 1-d 7 | 1/130 | 0.008 | 3/156 | 0.019 | 0.405 (0.043-3.849) | .432 |
| Late NM, day 8-d 27 | 1/130 | 0.008 | 1/156 | 0.006 | 1.215 (0.077-19.24) | .889 |
Thrombophilic vs nonthrombophilic women.